



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 937 456 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
25.08.1999 Bulletin 1999/34

(51) Int. Cl.⁶: **A61K 9/127, A61K 38/18**

(21) Application number: **98103111.5**

(22) Date of filing: **23.02.1998**

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(71) Applicant:
**Cilag AG International
6300 Zug (CH)**

(72) Inventors:
• **Näff, Rainer
CH-8246 Langwiesen (CH)**

• **Delmenico, Sandro
CH-8207 Schaffhausen (CH)**
• **Wetter, André
CH-8207 Schaffhausen (CH)**
• **Flöther, Frank-Ulrich
CH-8207 Schaffhausen (CH)**

(74) Representative:
**Blum, Rudolf Emil Ernst
c/o E. Blum & Co
Patentanwälte
Vorderberg 11
8044 Zürich (CH)**

(54) **Erythropoietin liposomal dispersion**

(57) The present invention relates to a liposome based formulation of erythropoietin comprising:

- (a) an effective amount of an erythropoietin;
- (b) a lipidic phase comprising:
 - (i) lecithin or hydrogenated lecithin;
 - (ii) optionally, a charged electropositive or electronegative lipid compound; and
 - (iii) cholesterol or a derivative thereof selected from cholesterol esters, polyethylene glycol derivatives of cholesterol (PEG-cholesterols), and organic acid derivatives of cholesterol; and
- (c) a phosphate buffer.

The liposome based parenteral dosage form of the invention is prepared by means of an ethanol injection technique. The composition avoids the need for use of human serum albumin and exhibits superior stability.

EP 0 937 456 A1

Description

FIELD OF THE INVENTION

5 [0001] The present invention relates to a liposome base formulation of erythropoietin. In particular, the invention relates to a liposome based parenteral dosage form of erythropoietin prepared by means of an ethanol injection technique which exhibits superior stability.

BACKGROUND OF THE INVENTION

10 [0002] Erythropoietin (EPO) is a glycoprotein which serves as the principal factor involved in the regulation of red blood cell synthesis. Erythropoietin is produced in the kidney and acts by stimulating precursor cells in the bone marrow causing them to divide and differentiate into mature red blood cells. The recombinantly produced 165 amino acid glycoprotein has been available for some time as an effective therapeutic agent in the treatment of various forms of anemia, including anemias associated with chronic renal failure, zidovudine treated HIV infected patients, and cancer patients on chemotherapy. The glycoprotein is administered parenterally, either as an intravenous (IV) or subcutaneous (SC) injection.

15 [0003] Presently, the parenteral formulations in use are conventional sterile buffered aqueous solutions for IV or SC injection which contain human serum albumin (HSA) as a carrier. Such formulations are marketed in the United States under the trade names EPOGEN® and PROCRIT®. These products contain erythropoietin in 1 ml single dose, preservative-free or 2 ml multidose preserved vials.

20 [0004] While these formulations have been proven to be highly successful, certain disadvantages are associated with the use of human serum albumin as carrier. As HSA is obtained from natural sources it can be a potential danger as a carrier for infectious disease agents such as HIV or hepatitis and careful screening of the material must be conducted. Further, the availability of appropriate quality of HSA can often be a problem. Hence, there is a need for an injectable formulation of erythropoietin which eliminates the use of HSA as a carrier.

25 [0005] Accordingly, attempts have been made to provide an improved formulation of erythropoietin which eliminates the use of HSA as a carrier. At the same time the formulation should be stable and provide an extended shelf life. Further, the formulation must avoid problems associated with the active ingredient adhering to the surface of the vial in which it is contained.

30 [0006] Liposomes are small vesicles comprising amphipathic lipids arranged in spherical bilayers. Liposomes may contain many concentric lipid bilayers separated by aqueous channels (multilamellar vesicles or MLVs), or alternatively, they may contain a single membrane bilayer (unilamellar vesicles), which may be small unilamellar vesicles (SUVs) or large unilamellar vesicles (LUVs). The lipid bilayer is composed of two lipid monolayers having a hydrophobic "tail" region and a hydrophilic "head" region. In the membrane bilayer, the hydrophobic "tails" of the lipid monolayers orient towards the center of the bilayer, whereas the hydrophilic "heads" orient toward the aqueous phase.

35 [0007] Liposomes may be used to encapsulate a variety of materials by trapping hydrophilic compounds in the aqueous interior or between bilayers, or by trapping hydrophobic compounds within the bilayer. As such, they are particularly useful to deliver biologically active materials by encapsulating compounds which exhibit poor aqueous solubility or which exhibit unacceptable toxicity at therapeutic dosages.

40 [0008] A specific method for the production of liposomes with only one double layer is disclosed in EP 253 619. Liposome formulations of various active agents have been known for years and liposomal preparations of erythropoietin have been proposed. For example, Maitani et al, J. Pharm. Sci., 85:440-445 (1996) discloses liposomal erythropoietin formulations intended for oral administration in which the liposomes are prepared by the reverse phase evaporation vesicle method. Since the formulation therein is intended for oral administration, a high percentage of incorporation of EPO into the liposomes is preferred. However, formulations such as this demonstrating a high rate of encapsulation in small vesicles may exhibit concentration in the liver, leading to toxicities. Moreover, the manufacturing procedures used therein require special raw materials (e.g. polyglycerine phospholipid) and the use of organic solvents. Further, the reverse phase process used therein suffers a high loss of unencapsulated EPO, which is undesirable and expensive.

50 [0009] The goal of the present invention therefore was to provide a parenteral formulation suitable for EPO, which avoids the use of HSA as carrier, provides acceptable long term stability for an extended shelf life, and which can be manufactured by means of a process which is amenable to large scale manufacture.

SUMMARY OF THE INVENTION

55 [0010] A liposome-based parenteral composition comprising:

(a) an effective amount of an active ingredient comprising erythropoietin or its pharmaceutically acceptable deriva-

tives having the biological properties of causing bone marrow cells to increase production of reticulocytes and red blood cells;

(b) a lipidic phase comprising:

- (i) lecithin or hydrogenated lecithin;
- (ii) optionally, a charged electropositive or electronegative lipid compound; and
- (iii) cholesterol or a derivative thereof selected from cholesterol esters, polyethylene glycol derivatives of cholesterol (PEG-cholesterols), and organic acid derivatives of cholesterol; and

(c) an aqueous buffer solution.

[0011] In accordance with the invention, the composition comprises single bilayered liposomes made by preparing an alcoholic solution of the lipidic phase and injecting the solution under pressure into an aqueous buffer solution contained in a high speed homogenizer. The liposomes thus prepared are incubated with the erythropoietin active ingredient to form the liposomal dispersion of the invention.

[0012] Preferably, the active ingredient is erythropoietin and its derivatives having the biological properties of causing bone marrow cells to increase production of reticulocytes and red blood cells. The EPO glycoprotein may be obtained from natural sources or produced recombinantly using known procedures as disclosed in U.S. patents 4,703,008, 5,441,868, 5,547,933, 5,618,698 and 5,621,080, hereby incorporated by reference.

[0013] In accordance with the present invention, it has been discovered that, quite unexpectedly, the liposomal EPO compositions prepared under the mild conditions described herein exhibit improved stability, i.e. the liposomes themselves are stable and at the same time the chemical degradation and aggregation of the biologically effective substance is minimized. As a further unexpected advantage, the EPO active ingredient does not adhere to the surface of the vial container or IV tubing even though the EPO is not substantially incorporated within the liposomes, but is instead essentially contained in the interstitial fluid as a liposomal dispersion.

DETAILED DESCRIPTION

[0014] The active ingredient used in the present invention is erythropoietin and its derivatives having the biological properties of causing bone marrow cells to increase production of reticulocytes and red blood cells. The liposomal dispersion of the present invention is useful as a parenteral formulation in treating blood disorders characterized by low or defective red blood cell production such as various forms of anemia, including anemias associated with chronic renal failure, zidovudine treated HIV infected patients, and cancer patients on chemotherapy. It may also have application in the treatment of a variety of disease states, disorders and states of hematologic irregularity such as sickle cell disease, beta-thalassemia, cystic fibrosis, pregnancy and menstrual disorders, early anemia of prematurity, spinal cord injury, space flight, acute blood loss, aging and the like. Preferably, the EPO composition of the present invention is administered parenterally (e.g. IV, IM, SC or IP). Effective dosages are expected to vary considerably depending on the condition being treated and the route of administration but are expected to be in the range of 0.1 (~7U) to 100 (~7000U) µg/kg body weight of the active material. Preferable doses for treatment of anemic conditions is about 50 to about 300 Units/kg three times a week.

[0015] The EPO liposomal dispersions of the present invention generally contain from about 200,000 Units to about 1 million Units of the EPO glycoprotein per 100 grams of composition. The active EPO ingredient is dispersed in a liposomal suspension formed from

(a) a lipidic phase comprising:

- (i) lecithin or hydrogenated lecithin;
- (ii) optionally, a charged electropositive or electronegative lipid compound; and
- (iii) cholesterol or a derivative thereof selected from cholesterol esters, polyethylene glycol derivatives of cholesterol (PEG-cholesterols), and organic acid derivatives of cholesterol; and

(b) an aqueous buffer solution.

[0016] Such a formulation, particularly produced according to the process described in EP 0 253 619, which is herein incorporated by reference, exhibits characteristics which make it a suitable substitute for the HSA containing compositions of the prior art.

[0017] Lecithin can either be used as natural lecithin in purified form or, preferably, as the more stable hydrogenated lecithin, whereby the use of the latter allows a reduction of the concentration of the stabilizing agents. The lecithin com-

ponent is generally present in an amount from about 0.5 to 5.0 grams per 100 grams of composition. Preferably, the hydrogenated lecithin should be of good quality without detectable levels of catalysts which can influence the stability of EPO and liposomes in a negative manner.

[0018] Cholesterol is employed as the liposome stabilizing agent in amounts ranging from 0.1 to 1.0 grams per 100 grams of composition. In addition to cholesterol, other cholesterol derivatives may be employed such as cholesterol esters, polyethylene glycol derivatives of cholesterol (PEG-cholesterols), as well as organic acid derivatives of cholesterol, for example cholesterol hemisuccinate.

[0019] The electropositive or electronegative lipid is a lipidic compound having a positively or negatively charged component. Electropositive lipids are oleyl amine or stearyl amine. Electronegative lipids are oleic acids, phosphatidic acids such as dipalmitoyl phosphatidic acid (DPPA), di-palmitoylglycerole (DPPG), distearoyl phosphatidic acid (DSPA), or dimyristyl phosphatidic acid (DMPA). The use of such charged lipids yields charged liposomes which guarantee an opalescent dispersion preventing the liposomes from sedimentation. As stated, the result is quite unexpected that the active erythropoietin glycoprotein does not adhere to the glass walls of the container or the silicon tubing used for its administration even though the active ingredient is not incorporated within the liposomes but merely exists as a dispersion with the charged liposomes.

[0020] An alcohol component comprised of a lower alkanol of one to six carbon atoms, such as methanol, ethanol, n-propanol, isopropanol, n-butanol and the like in amounts ranging from 0.5 to about 5.0 grams per 100 grams of composition is generally included in the composition prepared by use of the ethanol injection technique. Ethanol is preferred.

[0021] The aqueous buffer component is selected from the typical acid salts conventionally used as buffers in parenteral compositions. Examples include the citrates, acetates and phosphates. A phosphate buffer is preferred. Examples include sodium dihydrogen phosphate dihydrate, or di-sodium hydrogen phosphate dihydrate, and mixtures thereof. Preferably a mixture of sodium dihydrogen phosphate dihydrate and di-sodium hydrogen phosphate dihydrate in amounts ranging from 0 to 2.0g/100g is used.

[0022] Optionally, a stabilizer such as glycine can be added to the composition to prevent the formation of aggregates. However, in most cases such stabilizers are not necessary since the liposomes act as a stabilizer as well as a carrier in the composition.

[0023] The liposome-based compositions of the present invention are prepared by applying the methods known in the art for manufacturing liposome compositions described in EP 253619, hereby incorporated by reference. In this method single bilayered liposomes are prepared by preparing an ethanolic solution of a phospholipid and the active ingredient and injecting the solution under pressure into an aqueous buffer solution contained in a high speed homogenizer. The liposomes are formed spontaneously providing liposomes having a diameter of less than 1 μ m. In particular, in accordance with the method of the present invention, the liposomes are manufactured by forming an aqueous buffer solution in purified water. Separately, the lecithin, cholesterol and charged lipid component are dissolved in an alcoholic solution such as ethanol. The aqueous solution is connected to a high performance homogenizer to effect circulation and the alcoholic solution is directly injected into the homogenizer. Liposomes of less than 1 μ m are formed spontaneously. The liposomes thus formed are then incubated with the EPO active ingredient to form a liposomal dispersion of the invention.

[0024] To get a transparent liposome dispersion having liposomes with a well defined diameter, it is preferable to extrude the liposomes through filters with pores of about 0.05 - 0.08 mm resulting in liposomes with a diameter of about 80-100 nm. This additional particle sizing step is utilized to guarantee a transparent solution in order to easily detect any aggregations and to extend circulation time in the blood.

[0025] As stated above, the erythropoietin compositions currently marketed have stabilizers such as Tweens, amino acids etc or are stored dry frozen to maintain stability and have limited shelf-life. It has been found that the liposomal compositions of the present invention exhibit excellent stability, i.e. the liposomes themselves are stable and at the same time the decomposition and aggregation of the biologically effective substance is minimized. A shelf-life of up to 2 years has been achieved which is very important for industrial application. This improved stability may be attributable to the superior mild manufacturing technology of the present invention and the ingredients and composition of the formulation (both from a qualitative and quantitative point of view when compared with the formulations described in the literature).

[0026] The stability of the composition can be further enhanced by the addition of antioxidants such as tocopherol, butylated hydroxytoluene, butylated hydroxyanisole, ascorbyl palmitate, or edetates such as e.g. disodium edetate, with the edetates additionally binding possibly present heavy metals. The stability can furthermore be enhanced by the addition of preserving agents such as benzoic acid and parabens, e.g. methylparaben, and/or propylparabene.

[0027] Preferred compositions are those of the following general formula:

	g/100g
EPO or analogous compounds	200,000 U - 4 Mill. Units
Lecithin hydrogenated (Soya)	0.5 - 5.000
Cholesterol	0.1 - 1.000
Charged lipid	0.05 - 0.5
Ethanol	0.5 - 5.000
Glycine	0.0 - 1.00
Buffer	0 to 2.0
Further optional additives and water	q.s ad 100.0

[0028] The particular advantages of the present invention are further illustrated by the following examples:

20 EXAMPLE 1

Liposome-Based Dispersion

[0029] A liposome-based dispersion of the following composition was produced according to the method described in EP 0 253 619:

Composition:

30 [0030]

	g/100 g
Erythropoietin	1 Million I.U.
Lecithin (Soya) hydrogenated	0.500
Cholesterol	0.100
Ethanol Pharma Undenatured	0.500
Sodium Dihydrogenphosphate Dihydrate	0.1164
di-Sodium Hydrogen Phosphate Dihydrate	0.2225
Sodium Chloride	0.584
Water purified	97.9771

Procedure:

[0031] The liposomes are manufactured by forming an aqueous electrolyte (buffer) solution of the sodium dihydrogenphosphate dihydrate, di-sodium hydrogen phosphate dihydrate and sodium chloride in water for injection at 80 °C. Separately, the lecithin and cholesterol are dissolved in an alcoholic solution such as ethanol at 55 °C- 70 °C. The aqueous solution is connected to a high performance homogenizer to effect circulation (kettle 1) and the alcoholic solution (kettle 2) is directly injected into the homogenizer. The ethanol solution was purged with nitrogen during the whole procedure. Liposomes of less than 1 µm are formed spontaneously. To form liposomes with a well defined diameter the liposomal dispersion was extruded through nucleopore filters with defined pores (e.g. 0.8 and 0.5 µm). Erythropoietin was incubated with the liposomal dispersion and later one sterile filtration. Filling of the vials was done under aseptic conditions.

Technical data:

[0032]

- 5 Homogenizer speed: up to 13,000 rpm
 Flow rate of the ethanol solution: 20-100 ml/s

EXAMPLE 2

- 10 Liposome-Based Dispersion

Composition:

[0033]

15

	g/100 g
Erythropoietin	1 Million I.U.
Lecithin (Soya) hydrogenated	0.500
Cholesterol	0.100
DPPA-Na	0.040
Ethanol Pharma Undenatured	0.500
Sodium Dihydrogenphosphate Dihydrate	0.1164
di-Sodium Hydrogen Phosphate Dihydrate	0.2225
Sodium Chloride	0.584
Water purified	97.9371

20

25

30

Procedure:

35

[0034] The liposomal dispersion of Example 2 is prepared in accordance with the procedure of Example 1 with the exception that the DPPA-Na is added to the ethanol solution along with the lecithin and cholesterol prior to performing the ethanol injection.

40 EXAMPLE 3

Liposome-Based Dispersion

Composition:

45

[0035]

50

	g/100 g
Erythropoietin	1 Million I.U.
Lecithin (Soya) hydrogenated	0.500
Cholesterol	0.100
DPPG-Na	0.050
Ethanol Pharma Undenatured	0.500

55

(continued)

	g/100 g
Sodium Dihydrogenphosphate Dihydrate	0.1164
di-Sodium Hydrogen Phosphate Dihydrate	0.2225
Sodium Chloride	0.584
Water purified	97.9271

Procedure:

[0036] The liposomal dispersion of Example 3 is prepared in accordance with the procedure of Example 2.

EXAMPLE 4**Stability Testing**

[0037] Two batches of liposomal erythropoietin formulation were manufactured in accordance with the Examples 1 and 2. The batches were assayed for stability at various time intervals. The procedures for the in vitro and in vivo bioassays employed are set forth below. The results are set forth in Tables 1 and 2.

TABLE 1

Product: Erythropoietin Liposomal Formulation - EXAMPLE 1 BN: uncharged liposomes Dosage: 10'000 IU/ml						
Storage Time	Storage Conditions	Appearance	pH	EPO identity	ELISA	Bioassay
Initial	NA	pass	6.86	pass	9695	NA
3	2-8°C	pass	6.97	pass	9194	NA
3	25°C	pass	6.98	pass	8715	NA
6	2-8°C	pass	7.07	pass	9925	NA
6	25°C	pass	7.08	pass	7886	NA
9	2-8°C	pass	7.01	pass	9452	NA
12	2-8°C	pass	7.02	pass	9452	NA
18	2-8°C	N.A.	N.A.	pass*	8635	NA
24	2-8°C	pass	7.05	pass	9200	8900**

* = < 2% Aggregate standard (2%-AGG-1") by densitometry

** in vivo mouse bioassay

TABLE 2

Product: Erythropoietin Liposomal Formulation BN: negatively charged liposomes (Na-DPPA) Dosage: 10'000 IU/ml						
Storage Time	Storage Conditions	Appearance	pH	EPO identity	ELISA	Bioassay
Initial	NA	pass	6.71	pass	8757	10120
3	2-8°C	pass	7.03	pass	8776	8020
3	25°C	pass	7.02	pass	7854	N.A.
6	2-8°C	pass	7.02	pass	9621	7710
6	25°C	pass	7.06	pass	8453	N.A.
9	2-8°C	pass	7.03	pass	9189	8870
12	2-8°C	pass	N.A.	pass*	9150	N.A.
18	2-8°C	pass	6.99	pass	9003	9500**
24	2-8°C					NA

* = < 2% Aggregate standard (2%-AGG-1") by densitometry

** in vivo mouse bioassay, other are in vitro bioassay

In-vivo bioassay

[0038] Exhypoxic polycythemic mouse erythropoietin bioassay. Mice remain at reduced pressure for 18 hours. The following 6 hours the mice remain at ambient pressure. This procedure is repeated the following 14 days. After 3 days at ambient pressure erythropoietin is administered to the mice. After a day a solution containing $^{59}\text{FeCl}_3$ is injected. After another two days blood is analyzed and incorporation of $^{59}\text{FeCl}_3$ into erythrocytes is determined.

In-vitro bioassay

[0039] The in-vitro bioassay is a cell-based bioassay designed to accurately quantitate the biological activity of epoetin alfa.

[0040] The samples are first diluted in tissue culture medium and then treated with cell cultures of HEP.G2. This adherent cell line retains the capacity of hepatic tissue in its ability to remove desialated proteins. A similar metabolic process is known to occur in vivo, resulting in the reduced activity of desialated erythropoietin. Treatment with HEP.G2 cells will not remove sialated erythropoietin in epoetin alfa from the media. Thus, the in vitro bioassay mimics the mouse in vivo assay.

[0041] In the second step the remaining erythropoietin is separated from HEP.G2 cells and tested in a cell proliferation assay using the B6SutA cell line. These cells grow in the presence of erythropoietin and the extent of growth is proportional to the amount of erythropoietin. Cell growth is subsequently measured by the amount of color produced when MTT is added to the cells. The color generated is directly proportional to the number of cells and reducing activity of the B6SutA cells.

Conclusion

[0042] The data demonstrates a good stability of up to twenty-four months for both formulations.

Claims

1. A liposome-based parenteral composition comprising:

- (a) an effective amount of an active ingredient comprising erythropoietin or its pharmaceutically acceptable derivatives having the biological properties of causing bone marrow cells to increase production of reticulocytes and red blood cells;

(b) a lipidic phase comprising:

- (i) lecithin or hydrogenated lecithin;
- (ii) optionally, a charged electropositive or electronegative lipid compound and
- (iii) cholesterol or a derivative thereof selected from cholesterol esters, polyethylene glycol derivatives of cholesterol (PEG-cholesterols), and organic acid derivatives of cholesterol; and

(c) a phosphate buffer.

2. The composition of claim 1 wherein the composition comprises single bilayered liposomes made by preparing a solution of the lipidic phase in an alcoholic solvent and injecting the solution under pressure into the aqueous buffer solution contained in a high speed homogenizer.
3. The liposome-based formulation of claim 1 or 2, characterized in that it comprises furthermore a stabilizer.
4. The liposome-based formulation of claim 3, wherein the stabilizer is glycine.
5. The liposome-based formulation of anyone of claims 1 to 4, wherein the lecithin is hydrogenated lecithin.
6. The liposome-based formulation of anyone of claims 1 to 5, wherein the charged electropositive or electronegative lipid compound is selected from dipalmitoyl phosphatidic acid (DPPA), di-palmitoylglycerole (DPPG), oleyl amine and stearyl amine.
7. The liposome-based formulation of anyone of claims 1 to 6, wherein the buffer is selected from sodium dihydrogen phosphate dihydrate, di-sodium hydrogen phosphate dihydrate, and mixtures thereof.
8. The liposome-based formulation of anyone of claims 1 to 7, characterized in that it furthermore comprises a preserving agent.
9. The liposome-based formulation of anyone of claims 1 to 8, characterized in that it furthermore comprises an anti-oxidant.
10. The liposome-based formulation of anyone of claims 1 to 9, characterized in that it furthermore comprises a complexing agent.
11. The liposome-based formulation of anyone of claims 1 to 10, characterized in that it has the following composition:

	g/100g
EPO or analogous compounds	200,000 U - 1 Mill. Units
Lecithin hydrogenated (Soya)	0.5 - 5.000
Cholesterol	0.1 - 1.000
Charged lipid	0.05 - 0.5
Ethanol	0.5 - 5.000
Glycine	0.0 - 1.00
Buffer	0 to 2.0
Further optional additives and water	q.s ad 100.0.

12. The liposome-based formulation of anyone of claims 1 to 7 and 11, characterized in that it has the following composition:

	g/100 g
Erythropoietin	1 Million I.U.
Lecithin (Soya) hydrogenated	0.500
Cholesterol	0.100
DPPA-Na	0.040
Ethanol Pharma Undenatured	0.500
Sodium Dihydrogenphosphate Dihydrate	0.1164
di-Sodium Hydrogen Phosphate Dihydrate	0.2225
Sodium Chloride	0.584
Water purified	97.9371

13. The liposome-based formulation of anyone of claims 1 to 12 for use as a pharmaceutical preparation for the treatment of anemia.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 98 10 3111

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	DATABASE WPI Section Ch, Week 9646 Derwent Publications Ltd., London, GB; Class B04, AN 96-461276 XP002073043 & JP 08 231 417 A (CHUGAI PHARM CO LTD) * abstract *	1, 2, 13	A61K9/127 A61K38/18
X	US 5 569 464 A (KENJI ENDO ET AL.) 29 October 1996	1-4, 6, 8, 13	
Y	* column 2, line 28 - line 64 * * column 5, line 7 - line 8 * * column 5, line 59 - column 6, line 5; example 1 * * table 3 *	5, 7, 9-12	
Y	XIAN-RONG QI ET AL: "EVALUATION OF LIPOSOMAL ERYTHROPOIETIN PREPARED WITH REVERSE-PHASE EVAPORATION VESICLE METHOD BY SUBCUTANEOUS ADMINISTRATION IN RATS" CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 43, no. 2, 1 February 1995, pages 295-299, XP000494628 * abstract *	1-13	
D, Y	EP 0 253 619 A (CILAG LTD) 20 January 1988 * column 3, line 60 - column 4, line 48 * * column 5, line 8 - line 15 *	1-13	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 29 July 1998	Examiner Tzschoepe, D
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03/82 (P04/C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 10 3111

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29-07-1998

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5569464	A	29-10-1996	CA 2120197 A EP 0622072 A JP 6336442 A	03-10-1994 02-11-1994 06-12-1994

EP 0253619	A	20-01-1988	AU 598002 B AU 7538587 A CA 1302885 A DE 3776015 A DK 367187 A ES 2055703 T FI 873111 A,B GR 3003813 T HK 78492 A IE 60469 B JP 2574309 B JP 63116737 A KR 9502146 B	14-06-1990 21-01-1988 09-06-1992 27-02-1992 16-01-1988 01-09-1994 16-01-1988 16-03-1993 23-10-1992 13-07-1994 22-01-1997 21-05-1988 14-03-1995

EPU FJHM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82